Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5. On July 29, Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138. This is a potent and selective oral inhibitor of interleukin-2-inducible T cell kinase/ITK and Janus kinase 3/JAK3, which are both enzymes involved in immune responses.

The trial was an open-label, single-arm study conducted with 14 patients who had moderate-to-severe atopic dermatitis/AD. The company intends to further develop ATI-2138 for alopecia areata and other immuno-inflammatory diseases. The trial successfully achieved its primary and key secondary endpoints.

The primary endpoint, which focused on safety, confirmed that ATI-2138 has a favorable tolerability profile without the significant safety risks often associated with other JAK inhibitors. No severe adverse events/SAEs or treatment-emergent adverse events/TEAEs were observed. The efficacy results showed clinically meaningful improvements in disease severity.

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the US.

While we acknowledge the potential of ACRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.